BUSINESS● LOWSep 9 · Sep 9, 2026, 4:53 PM
Ocugen slips after interim trial data for Stargardt disease candidate
Seeking Alpha Tech · north america
Ocugen's stock declined following the release of interim trial data for its Stargardt disease candidate. This indicates a market reaction to the experimental treatment's progress.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS7m agoOil hits five-month high amid fears of fresh strikes on IranThe TelegraphBUSINESS17m agoPackages by plane: Mercado Libre grows in the air shipping business and opens a new logistics center in MendozaClarín